Effects of risedronate: A Synthesis of Findings from 2 Studies

  1. Home
  2. Effects of risedronate
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of risedronate: A Synthesis of Findings from 2 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of risedronate: A Synthesis of Findings from 2 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Randomized clinical trials have shown that risedronate reduces the risk for both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis (bone mineral density [BMD] T-score, <-2.5). 1 Risedronate sodium, a pyridinyl bisphosphonate, is an antiresorptive drug approved by the US Food and Drug Administration for the prevention and treatment of osteoporosis in postmenopausal women. 1 Although the effects of risedronate in preventing fractures has been established, its effects in maintaining or increasing BMD in osteopenia have not. 1 Treatment with once weekly risedronate 35 mg is able to decrease CTX and bone ALP compared with risedronate 5 mg once daily, in postmenopausal women with osteoporotic fractures. 2 This therapeutic protocol may provide an alternative for patients who prefer once-a-week oral dosing. 2

Benefits and Risks

Benefit Summary

Risedronate has been shown to reduce the risk for both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis (bone mineral density [BMD] T-score, <-2.5). 1 Treatment with once weekly risedronate 35 mg is able to decrease CTX and bone ALP compared with risedronate 5 mg once daily, in postmenopausal women with osteoporotic fractures. 2 This therapeutic protocol may provide an alternative for patients who prefer once-a-week oral dosing. 2

Risk Summary

Risedronate may cause gastrointestinal side effects. 2 Consult with a doctor before taking risedronate. 1

Comparison of Studies

Commonalities of Studies

Both studies indicate that risedronate impacts bone metabolism in postmenopausal women. 1 2 Both studies show that risedronate may be effective in treating osteoporosis. 1 2

Differences of Studies

The paper 1 focuses on the effects of risedronate on maintaining or increasing BMD in women with osteopenia. The paper 2 compares the effects of once weekly 35 mg risedronate to 5 mg once daily risedronate in women with osteoporosis.

Consistency and Discrepancies in Results

Risedronate may be effective in treating osteoporosis in postmenopausal women. 1 2 However, the effects of risedronate on maintaining or increasing BMD in women with osteopenia are unclear. 1 Future research is needed to further investigate the effects of risedronate in women with osteopenia.

Application to Real-World Settings

Risedronate may be effective in treating osteoporosis, but it can cause gastrointestinal side effects. 2 Consult with a doctor before taking risedronate. 1 If you are at risk for osteopenia or osteoporosis, it is important to talk to your doctor to discuss treatment options, including risedronate. 1

Limitations of Current Research

These studies did not assess the long-term effects of risedronate or the effects of risedronate on different types of fractures. 1 2 Future research is needed to address these important issues.

Future Research Directions

Further research is needed to evaluate the long-term effects of risedronate and the effects of risedronate on different types of fractures. 1 2 Research is also needed to investigate the effects of risedronate in women with osteopenia. 1

Conclusion

Risedronate has been shown to reduce the risk for both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis (bone mineral density [BMD] T-score, <-2.5). 1 Risedronate sodium, a pyridinyl bisphosphonate, is an antiresorptive drug approved by the US Food and Drug Administration for the prevention and treatment of osteoporosis in postmenopausal women. 1 Treatment with once weekly risedronate 35 mg is able to decrease CTX and bone ALP compared with risedronate 5 mg once daily, in postmenopausal women with osteoporotic fractures. 2 This therapeutic protocol may provide an alternative for patients who prefer once-a-week oral dosing. 2 If you are at risk for osteopenia or osteoporosis, it is important to talk to your doctor to discuss treatment options, including risedronate. 1 Further research is needed to evaluate the long-term effects of risedronate and the effects of risedronate on different types of fractures. 1 2

Keywords
Benefit Keywords
Increased BMD
Reduced fractures
1
Osteoporosis treatment
2
Risk Keywords
Literature analysis of 2 papers
Positive Content
2
Neutral Content
0
Negative Content
0
Article Type
2
0
0
0
2
1.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Author: VälimäkiMatti J, Farrerons-MinguellaJordi, HalseJohan, KrögerHeikki, MaroniMarilyn, MulderHenk, Muñoz-TorresManuel, SääfMaria, Snorre ØfjordErik

Increased BMD
Reduced fractures

The study discussed the use of risedronate for the prevention and treatment of osteoporosis in postmenopausal women, highlighting the need for research on its effects in maintaining or increasing bone mineral density (BMD) in osteopenia.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.

Author: BahlousAfef, BouzidKahena, SahliHéla, SallamiSlaheddine, AbdelmoulaJaouda

Osteoporosis treatment

Risedronate 35 mg once a week is as effective as 5 mg once daily in decreasing CTX and bone ALP in postmenopausal women with osteoporotic fractures. Both doses were well-tolerated.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.